Wealth Enhancement Advisory Services LLC Grows Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Wealth Enhancement Advisory Services LLC grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 1.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,434 shares of the medical research company’s stock after buying an additional 56 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in IQVIA were worth $1,068,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in IQV. Private Trust Co. NA grew its position in IQVIA by 10.7% in the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after acquiring an additional 47 shares in the last quarter. Clear Harbor Asset Management LLC boosted its holdings in shares of IQVIA by 1.3% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock worth $941,000 after purchasing an additional 50 shares during the period. Pine Valley Investments Ltd Liability Co increased its position in shares of IQVIA by 0.5% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after purchasing an additional 50 shares during the last quarter. Fortitude Family Office LLC raised its holdings in IQVIA by 2.9% during the 3rd quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock valued at $468,000 after buying an additional 56 shares during the period. Finally, Huntington National Bank lifted its position in IQVIA by 7.4% in the third quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock worth $192,000 after buying an additional 56 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on IQV. William Blair reiterated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft cut their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Redburn Atlantic began coverage on shares of IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. Royal Bank of Canada restated an “outperform” rating and set a $270.00 target price on shares of IQVIA in a research report on Wednesday, December 11th. Finally, TD Cowen reduced their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $255.82.

IQVIA Stock Down 1.0 %

NYSE:IQV opened at $196.01 on Thursday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The company has a 50-day moving average of $201.43 and a 200 day moving average of $221.61. The firm has a market cap of $35.58 billion, a PE ratio of 25.72, a price-to-earnings-growth ratio of 2.05 and a beta of 1.48.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.